Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

lung cancer patients

- PMLiVE

Daily Brief: Italy in turmoil, Pharma attacks Europe’s generics move and more

A rapid round up of news from pharma, biotech and healthcare

- PMLiVE

Daily Brief: AstraZeneca’s new San Fran home, Keytruda triumphs again, Novo branches out

A rapid round up from pharma, biotech and healthcare

AstraZeneca AZ

AstraZeneca expands alliance with Bicycle Therapeutics

Collaboration to seek out new respiratory and cardio-metabolic drugs

- PMLiVE

Better times ahead, promises AZ as Crestor drop outweighs new drugs

Patent expiry fading says Soriot, as oncology prospects look good

- PMLiVE

AstraZeneca and Emulate advance ‘organs-on-chips’ research partnership

Company advances partnership, aiming to integrate technology into full-scale R&D efforts

- PMLiVE

Daily brief:  Trump fails to ruffle PBMs, pharma, Jowell leaves brain tumour research legacy

A rapid round-up of recent happenings, plus some key events taking place this week

- PMLiVE

AZ’s Fasenra hit by COPD trial failure

Results give advantage to respiratory rivals GSK

AstraZeneca AZ

Maintenance OK boosts AstraZeneca’s Lynparza in Europe

New pill formulation also helps AZ and MSD against competitors in PARP class

- PMLiVE

Redx poaches AstraZeneca senior executive

Lisa Anson joins the UK biotech as its CEO

AstraZeneca AZ

AZ’s immuno-oncology combo fails another lung cancer trial

Latest failure casts doubt on company’s CTLA4 drug

- PMLiVE

AZ makes case for first-line Tagrisso therapy in lung cancer

Data shows the drug improved PFS versus older EGFR inhibitors including Roche’s Tarceva

- PMLiVE

Merck’s Keytruda scores in frontline lung cancer yet again

Drug improved overall survival as a monotherapy, which rival BMS’ Opdivo was unable to show

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links